Insuman Comb 30

Insulin Human, the active ingredient in Insuman Comb 30, is an insulin presented as an injectable solution for subcutaneous use. It treats type 1 and type 2 diabetes mellitus by providing both basal and prandial insulin coverage. GNH USA supplies Insuman Comb 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Comb 30 is an insulin preparation used to manage blood glucose in diabetes mellitus and related insulin‑deficiency states. - Type 1 diabetes mellitus: provides basal and prandial insulin to achieve target glucose levels. - Type 2 diabetes mellitus: supplements endogenous insulin to improve glycaemic control. - Insulin deficiency states: replaces missing insulin to maintain glucose homeostasis.

Insuman Comb 30 may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased adipose tissue due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Mild allergic reactions: urticaria or localized rash. - Edema: peripheral fluid accumulation.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment requiring immediate assistance. - Anaphylaxis: systemic allergic reaction with airway compromise. - Insulin allergy: generalized rash, bronchospasm, or angio‑edema. - Lipohypertrophy: large, painful fatty deposits that affect insulin absorption. - Hypokalemia: low serum potassium in rare cases. - Acute insulin resistance: unexpected loss of insulin efficacy.

When using Insuman Comb 30, several safety considerations are recommended. - Dose adjustment: tailor the dose based on regular glucose monitoring and clinical response. - Renal impairment: monitor closely as reduced clearance may increase hypoglycaemia risk. - Hepatic impairment: use with caution; altered metabolism can affect glucose control. - Pregnancy: limited safety data; weigh maternal benefits against potential fetal risks. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 30 can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection. - MAO inhibitors: can cause unpredictable glucose fluctuations. - Oral contraceptives: may increase insulin requirements.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose levels. - Corticosteroids: can increase insulin needs due to hyperglycaemic effect. - ACE inhibitors: may enhance insulin sensitivity, potentially leading to hypoglycaemia.